Regional Scientific Director, Great Lakes Region
Intellia Therapeutics, Inc.
10 hours ago
On-site
South Dakota, United States
$216,000 - $264,000 USD yearly
Medical Affairs
Responsibilities
- Engage with KOLs across ATTR amyloidosis and HAE to provide education on CRISPR gene editing, and reactively share MoA and clinical data for nex-z and lonvo-z.
- Understand patient journey at key centers; identify site capabilities and preferences for gene editing.
- Develop individualized scientific engagement plans for key KOLs aligned with scientific narrative and medical strategy.
- Identify external insights and knowledge gaps; report timely via CRM.
- Attend medical congresses to support KOL engagement, medical booth staffing, scientific session coverage, insights gathering, and reporting.
- Deliver institutional presentations on scientific evidence as appropriate.
- Provide scientific support for Phase 3 trial site start-up, activation, and recruitment.
- Establish, cultivate, and maintain scientific relationships with Investigators and study site teams.
- Identify barriers to site activation/patient recruitment and collaborate to develop solutions.
- Escalate site feedback/concerns to clinical teams.
- Maintain a robust understanding of clinical practice and referral associated with gene editing therapies.
- Ensure compliance and scientific integrity (complete trainings on time; adhere to policies).
Qualifications / Requirements
- Doctorate level or terminal degree (Pharm.D., Ph.D., M.D., or D.O.).
- 3+ years industry or related field experience.
- Extensive clinical trial experience, including Phase 3 trials.
- Prior pharmaceutical industry experience as an MSL/RSD; strong understanding of scientific exchange in compliance/regulatory environments.
- Valid driver’s license.
Preferred Qualifications / Skills
- Therapeutic knowledge in allergy/immunology/HAE, cardiology/ATTR-CM/-PN, or genetic medicine.
- New product launch experience.
- Ability to travel 50–70% (including overnight stays).
Application instructions
- Applications accepted on a rolling basis until the position is filled.
- Engage with KOLs across ATTR amyloidosis and HAE to provide education on CRISPR gene editing, and reactively share MoA and clinical data for nex-z and lonvo-z.
- Understand patient journey at key centers; identify site capabilities and preferences for gene editing.
- Develop individualized scientific engagement plans for key KOLs aligned with scientific narrative and medical strategy.
- Identify external insights and knowledge gaps; report timely via CRM.
- Attend medical congresses to support KOL engagement, medical booth staffing, scientific session coverage, insights gathering, and reporting.
- Deliver institutional presentations on scientific evidence as appropriate.
- Provide scientific support for Phase 3 trial site start-up, activation, and recruitment.
- Establish, cultivate, and maintain scientific relationships with Investigators and study site teams.
- Identify barriers to site activation/patient recruitment and collaborate to develop solutions.
- Escalate site feedback/concerns to clinical teams.
- Maintain a robust understanding of clinical practice and referral associated with gene editing therapies.
- Ensure compliance and scientific integrity (complete trainings on time; adhere to policies).
Qualifications / Requirements
- Doctorate level or terminal degree (Pharm.D., Ph.D., M.D., or D.O.).
- 3+ years industry or related field experience.
- Extensive clinical trial experience, including Phase 3 trials.
- Prior pharmaceutical industry experience as an MSL/RSD; strong understanding of scientific exchange in compliance/regulatory environments.
- Valid driver’s license.
Preferred Qualifications / Skills
- Therapeutic knowledge in allergy/immunology/HAE, cardiology/ATTR-CM/-PN, or genetic medicine.
- New product launch experience.
- Ability to travel 50–70% (including overnight stays).
Application instructions
- Applications accepted on a rolling basis until the position is filled.